Related Experiment Video

Updated: Jul 13, 2026

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Targeted therapy for renal cell carcinoma: a new treatment paradigm

Thomas E Hutson1

  • 1Genitourinary Oncology Program, Department of Oncology, Baylor Charles A. Sammons Cancer Center, Dallas, Texas, USA. thomas.hutson@usoncology.com

Proceedings (Baylor University. Medical Center)
|July 20, 2007
PubMed

Insights

Novel targeted therapies, including vascular endothelial growth factor inhibitors and mTOR pathway agents, have significantly improved outcomes for metastatic clear cell renal cell cancer, offering a promising future for treatment.

Area of Science:

  • Oncology
  • Medical Science

Background:

  • Metastatic clear cell renal cell cancer (mccRCC) was historically treated with cytokine-based therapies like interferon and interleukin-2.
  • Advances in understanding tumor biology have led to the development of novel targeted therapeutic agents.
  • Key pathways targeted include vascular endothelial growth factor (VEGF) and the mTOR signal transduction pathway.

Purpose of the Study:

  • To review the impact of novel targeted therapeutic agents on the treatment of metastatic clear cell renal cancer.
  • To highlight agents that have demonstrated improved clinical outcomes in recent trials.
  • To discuss the potential of combination therapies and future directions in renal cancer treatment.

Main Methods:

  • Review of randomized clinical trials and early studies evaluating targeted agents in mccRCC.
  • Analysis of drugs targeting VEGF pathway and mTOR pathway.
  • Exploration of multitargeted tyrosine kinase inhibitors and antiangiogenic agents.

Main Results:

  • Sunitinib malate, sorafenib tosylate, temsirolimus, and bevacizumab have shown improved clinical outcomes in randomized trials.
  • Other agents like lapatinib, axitinib, pazopanib, VEGF Trap, and lenalidomide have demonstrated activity in early studies.
  • Combination therapies are currently under evaluation.

Conclusions:

  • Novel targeted agents have significantly altered the natural history of metastatic clear cell renal cell cancer.
  • The efficacy of these new agents suggests a promising future for renal cancer therapy.
  • Continued research into targeted therapies and combinations holds potential for further advancements.

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...